{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T10:21:18Z","timestamp":1756462878579},"reference-count":9,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,1]]},"DOI":"10.1097\/cad.0000000000000023","type":"journal-article","created":{"date-parts":[[2013,9,4]],"date-time":"2013-09-04T17:42:39Z","timestamp":1378316559000},"page":"101-105","source":"Crossref","is-referenced-by-count":12,"title":["Liposome-encapsulated doxorubicin citrate (Myocet) for treatment of recurrent epithelial ovarian cancer"],"prefix":"10.1097","volume":"25","author":[{"given":"Ram","family":"Eitan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ami","family":"Fishman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michai","family":"Meirovitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hadassah","family":"Goldenberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amnon","family":"Amit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claude","family":"Koren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yulia","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ora","family":"Rosengarten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Avivit","family":"Neuman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shoshanna","family":"Keren-Rosenberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tamar","family":"Safra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-12-20210227","doi-asserted-by":"crossref","first-page":"225","DOI":"10.3322\/caac.20006","article-title":"Cancer statistics, 2009.","volume":"59","author":"Jemal","year":"2009","journal-title":"CA Cancer J Clin"},{"key":"R3-12-20210227","first-page":"723","article-title":"Recurrent ovarian cancer.","volume":"3","author":"Tummala","year":"2005","journal-title":"Clin Adv Hematol Oncol"},{"key":"R4-12-20210227","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/978-1-60327-492-0_20","article-title":"Epidemiology of ovarian cancer.","volume":"472","author":"Permuth-Wey","year":"2009","journal-title":"Methods Mol Biol"},{"key":"R5-12-20210227","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.ygyno.2009.11.033","article-title":"Achievements and unmet needs in the management of advanced ovarian cancer.","volume":"117","author":"Guarneri","year":"2010","journal-title":"Gynecol Oncol"},{"key":"R7-12-20210227","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1200\/JCO.1995.13.3.726","article-title":"Impact of doxorubicin on survival in advanced ovarian cancer.","volume":"13","author":"AHern","year":"1995","journal-title":"J Clin Oncol"},{"key":"R8-12-20210227","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1006\/gyno.2000.5921","article-title":"Phase 2 trial of liposomal doxorubicin (40 mgm(2)) in platinumpaclitaxel-refractory ovarian and fallopian tube cancers and primary carcinoma of the peritoneum.","volume":"78","author":"Markman","year":"2000","journal-title":"Gynecol Oncol"},{"key":"R11-12-20210227","doi-asserted-by":"crossref","first-page":"3312","DOI":"10.1200\/JCO.2001.19.14.3312","article-title":"Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan.","volume":"19","author":"Gordon","year":"2001","journal-title":"J Clin Oncol"},{"key":"R13-12-20210227","doi-asserted-by":"crossref","first-page":"3185","DOI":"10.1200\/JCO.1997.15.10.3185","article-title":"Treatment of advanced breast cancer with sterically stabilized liposomal doxorubicin: results of a multicenter phase II trial.","volume":"15","author":"Ranson","year":"1997","journal-title":"J Clin Oncol"},{"key":"R18-12-20210227","doi-asserted-by":"crossref","first-page":"187s","DOI":"10.1200\/JCO.2003.01.223","article-title":"Use of CA-125 to assess response to new agents in ovarian cancer trials.","volume":"21","author":"Rustin","year":"2003","journal-title":"J Clin Oncol"}],"container-title":["Anti-Cancer Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CAD.0000000000000023","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,13]],"date-time":"2021-05-13T23:01:08Z","timestamp":1620946868000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00001813-201401000-00012"}},"subtitle":["a retrospective analysis"],"short-title":[],"issued":{"date-parts":[[2014,1]]},"references-count":9,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.1097\/cad.0000000000000023","relation":{},"ISSN":["0959-4973"],"issn-type":[{"value":"0959-4973","type":"print"}],"subject":[],"published":{"date-parts":[[2014,1]]}}}